Dermatitis Research Today is a free monthly online journal that collates and summarizes the latest research about Dermatitis, including details on contact-, seborrheic-, atopic-, allergic-dermatitis, treatment.

Volume 3 (2006), Issue 8 (August)

1. Inhibition of the TPA-induced cutaneous inflammation and hyperplasia by EC-SOD.
   Biochem Biophys Res Commun, 348(2): 450-8. [Abstract] [Full-text]
2. Description and management of cutaneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patients.
   J Am Acad Dermatol, 55(3): 429-37. [Abstract] [Full-text]
3. Neuropeptide control mechanisms in cutaneous biology: physiological and clinical significance.
   J Invest Dermatol, 126(9): 1937-47. [Abstract] [Full-text]
4. Bioactivation, protein haptenation, and toxicity of sulfamethoxazole and dapsone in normal human dermal fibroblasts.
   Toxicol Appl Pharmacol, 215(2): 158-67. [Abstract] [Full-text]
5. Induction of atopic eczema/dermatitis syndrome-like skin lesions by repeated topical application of a crude extract of Dermatophagoides pteronyssinus in NC/Nga mice.
   Int Immunopharmacol, 6(10): 1616-22. [Abstract] [Full-text]
6. A new chronic itch model accompanied by skin lesions in hairless mice.
   Int Immunopharmacol, 6(10): 1609-15. [Abstract] [Full-text]
7. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys.
   Lancet, 368(9537): 733-43. [Abstract] [Full-text]
8. Structural fat grafting: more than a permanent filler.
   Plast Reconstr Surg, 118(3): 108S-120S. [Abstract] [Full-text]
9. 17beta-estradiol enhances contact hypersensitivity and IFN-gamma expression in inflamed skin of BALB/c mice.
   Toxicol Lett, 166(1): 60-6. [Abstract] [Full-text]
10. Reduced incidence of cervical cancer in mothers of sons with allergic rhinoconjunctivitis, asthma or eczema.
    Int J Cancer, 119(8): 1994-8. [Abstract] [Full-text]

© 2004-2008 Dermatitis Research Today. All Rights Reserved.